Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Synovitis Clear all
Completed No phase listed Observational Results available

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

NCT02948088
View directory record Official record
Conditions
Giant Cell Tumors
Interventions
Not listed
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 15, 2026, 9:34 AM EDT
Completed No phase listed Observational

A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome

NCT00890058
View directory record Official record
Conditions
Arthralgia Syndrome, Arthritis, Synovitis
Interventions
Not listed
Lead sponsor
Victoria Shanmugam
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 15, 2026, 9:34 AM EDT
Completed No phase listed Observational

Accuracy of Pediatric Emergency Medicine Providers in Diagnosing Hip Effusions Using Point of Care Ultrasound

NCT05971745
View directory record Official record
Conditions
Hip Effusion, Septic Arthritis, Transient Synovitis, Hip
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
1 Month to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Hartford, Connecticut • New Haven, Connecticut • Newark, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 15, 2026, 9:34 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT04192344
View directory record Official record
Conditions
Neoplasms, Tenosynovial Giant Cell Tumor
Interventions
ABSK021
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

NCT00001677
View directory record Official record
Conditions
Arthritis, Rheumatoid, Synovitis
Interventions
Methotrexate, Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional

MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE

NCT03355482
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
Methylprednisolone, Placebos
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 15, 2026, 9:34 AM EDT
Completed No phase listed Observational

Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions

NCT00001291
View directory record Official record
Conditions
Arthritis, Psoriatic, Autoimmune Diseases, Joint Diseases, Osteoarthritis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

NCT02371369
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Not applicable Interventional

Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound

NCT02902562
View directory record Official record
Conditions
Synovitis, Rheumatoid Arthritis
Interventions
Contrast Enhanced Ultrasound (CEUS), Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 3 Interventional

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

NCT01213017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
certolizumab pegol
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Aventura, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

NCT02471716
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Interventions
FPA008
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Results available

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

NCT03291288
View directory record Official record
Conditions
Drug Interaction Potential
Interventions
Tolbutamide, Midazolam, Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease

NCT00212485
View directory record Official record
Conditions
Inherited Bleeding Disorders
Interventions
Power Doppler Sonography, MRI
Procedure
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
1 Year to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 15, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

NCT05349643
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
Interventions
AMB-05X
Biological
Lead sponsor
AmMax Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Sacramento, California • Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 15, 2026, 9:34 AM EDT
Recruiting No phase listed Observational

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

NCT04635111
View directory record Official record
Conditions
Hepatotoxicity, Tenosynovial Giant Cell Tumor
Interventions
TURALIO™
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
8
States / cities
Santa Monica, California • Whittier, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 15, 2026, 9:34 AM EDT